Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions

NATerminatedINTERVENTIONAL
Enrollment

394

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

October 31, 2012

Conditions
Coronary Atherosclerosis
Interventions
DEVICE

NEVO™ Sirolimus-eluting Coronary Stent System

Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.

DEVICE

Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)

Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.

Trial Locations (2)

04012-909

Instituto Dante Pazzanese de Cardiologia, São Paulo

Unknown

Mercy Angiography Unit, Epsom

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Conor Medsystems

INDUSTRY

lead

Cordis Corporation

INDUSTRY